The bill providing for a referendum on UK membership of the European Union is now before the UK House of Commons. The referendum will be held before the end of 2017. A British exit from the European Union would have a profound impact on British and EU health policies as well as on pharmaceutical regulation (one of the longest standing harmonised sectors) and on pharmaceutical companies operating in Europe.
This panel discussion will explore the impact of a potential 'Brexit' for the EU, UK, Industry, life sciences and patients.
Andrew Hollingsworth - Former Policy Manager, ABPI and Cancer Research UK
Elizabeth Kuiper - Director European Affairs, EFPIA
Nina Renshaw - Secretary General, EPHA
Ian Schofield - Analyst, Scrip Intelligence
To RSVP, email email@example.com
37 Square de Meeus
Google map and directions